An investigation of the effects of helminth worm infection on the capacity of HIV vaccines to boost vaccine-generated immune responses

Master Thesis

2017

Permanent link to this Item
Authors
Journal Title
Link to Journal
Journal ISSN
Volume Title
Publisher
Publisher

University of Cape Town

License
Series
Abstract
To protect against sexual transmission, successful future HIV vaccines will likely be given to adolescents as a booster subsequent to primary immunization during infancy. In sub-Saharan Africa (SSA), a large proportion of children are chronically infected with a variety of helminths. These infections may suppress the ability of a host to elicit vaccine-induced Th1 responses that are considered important for a successful HIV vaccine. This study investigated the effect of chronic helminthic infection on the boosting capacity of a poxvirus-protein HIV vaccine regimen (SAAVI MVA-C and Env gp140 protein) in a mouse model. Groups of mice were prime-vaccinated with SAAVI MVA-C through an intramuscular injection, and Env gp140 protein formulated in Alum adjuvant which was administered via an intraperitoneal injection. These vaccinations were given concurrently, 2 weeks prior to infection with Schistosoma mansoni (Sm) through a percutaneous route. Control mice were either left uninfected (Naïve) or infected in the same manner (Sm) without vaccination. A booster vaccination was given 8 weeks post helminth infection. HIV-specific immune responses were analysed in the blood and spleens two weeks after booster vaccination. The magnitudes of cumulative IFN-γ ELISPOT responses to HIV Gag, RT and Env peptides were significantly (p<0.05) lower in the vaccinated and Sm-infected (Vaccine+Sm) mice (948 sfu/106) than vaccinated and uninfected (Vaccine) mice (1733 sfu/106), with IFN-γ responses to RT (CD8) being the most dominant for both mouse groups (Vaccine+Sm: 734 ± 221 sfu/106, Vaccine: 521 ± 116 sfu/106). No significant difference was observed in the magnitudes of cumulative IL-2 ELISPOT responses to the vaccine peptides between the Vaccine+Sm and Vaccine groups, however IL-2-producing T cell responses to Env (CD4) dominated in both mouse groups. Vaccine+Sm and Sm groups had similar IFN-γ- and IL-2-producing T cell responses to SEA. Splenocytes from Vaccine+Sm mice secreted less Th1 (IFN-γ, IL-2, TNF- α) and Th2 (IL-4, IL-6, IL-10) cytokines than those from uninfected vaccinated mice in response to HIV vaccine peptides. The total number of activated CD4+ T cells responding to vaccine peptides was greater for Vaccine+ Sm mice than Vaccine mice (p<0.05), however, no such statistical significance was observed in the differences seen between these vaccinated mouse groups for the number of activated CD8+ T cells. The frequencies of central memory activated CD4+ T cells were seen to be greater in Vaccine group (Gag; 34.28 ± 8.35%, Pol; 33.53 ± 6.34%, Env(CD4); 33.92 ± 3.87%, Env (CD8); 38.76 ± 10.52%) as opposed to the Vaccine+Sm group (Gag; 28.09 ± 3.95%, Pol; 26.45 ± 4.66%, Env (CD4); 28.79 ± 6.95%, Env (CD8); 28.65 ± 3.29%). Furthermore, Vaccine+Sm mice had higher titres of HIV-1 gp140- specific IgG1 antibodies (p<0.0001) (a Th2 antibody marker) but significantly less gp140- specific IgG2a (p<0.0001) and IgG2b (p<0.001) (Th1 antibody markers) antibodies. This trend was also observed with total non-Env-specific antibody titres. This study demonstrates that chronic helminthic infection is associated with an attenuated boosting capacity of a poxvirus-protein HIV vaccine in a mouse model, suppressing both T cell cytokine production and Th1-type antibody responses. Since HIV vaccine-induced Th1 responses are considered important for a successful HIV vaccine, these data suggest that chronic helminthiasis may impact negatively on future HIV vaccination outcomes in adolescents living in SSA where helminthic parasites are endemic.
Description

Reference:

Collections